Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026
Cannabis and Tobacco Co-Use Is Associated With Impaired Neurocognitive Performance in Individuals at Clinical High Risk for Psychosis.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bello Daniel, Connolly Jillian G, Addington Jean, Bearden Carrie E, Cadenhead Kristin, Cannon Tyrone D, Cornblatt Barbara, Keshavan Matcheri, Mathalon Daniel H, Perkins Diana O, Seidman Larry, Stone William S, Tsuang Ming T, Walker Elaine F, Woods Scott, Brady Roscoe O, Carrión Ricardo E, Ward Heather Burrell
Аннотация
BACKGROUND: Cannabis use is highly prevalent among people with psychotic disorders. While there is some indication that cannabis use exacerbates psychosis symptoms, its neurocognitive effects remain unclear. Co-use of cannabis and tobacco is increasing in the general population, but little is known about its effects in people with psychosis or those at risk for developing a psychotic disorder, including its effects on cognitive performance.
METHODS: We analyzed data from NAPLS2 (North American Prodrome Longitudinal Study 2), a multisite prospective study of individuals at clinical high risk for psychosis (CHR-P) and healthy control participants. Cognitive performance was assessed using the MATRICS Consensus Cognitive Battery and the Seidman Auditory Continuous Performance Task. We examined differences in cognitive performance across 6 study groups: 1) CHR-P tobacco use, 2) CHR-P cannabis use, 3) CHR-P co-use, 4) CHR-P with neither tobacco nor cannabis use, 5) CHR-P with no substance use, and 6) healthy control.
RESULTS: Among 1012 participants (734 CHR-P, 278 healthy control), co-use of cannabis and tobacco was associated with lower global cognitive performance and lower working memory, verbal learning, and attentional performance compared with healthy control participants. CHR-P individuals who did not use substances also had lower cognitive performance across multiple measures, including global cognition, working memory, verbal learning, visual learning, and attentional performance. The CHR-P non-substance use group also had the lowest social functioning.
CONCLUSIONS: Cannabis and tobacco co-use is associated with lower neurocognitive performance, which may explain the mixed associations between cannabis use and cognitive performance in previous literature.
METHODS: We analyzed data from NAPLS2 (North American Prodrome Longitudinal Study 2), a multisite prospective study of individuals at clinical high risk for psychosis (CHR-P) and healthy control participants. Cognitive performance was assessed using the MATRICS Consensus Cognitive Battery and the Seidman Auditory Continuous Performance Task. We examined differences in cognitive performance across 6 study groups: 1) CHR-P tobacco use, 2) CHR-P cannabis use, 3) CHR-P co-use, 4) CHR-P with neither tobacco nor cannabis use, 5) CHR-P with no substance use, and 6) healthy control.
RESULTS: Among 1012 participants (734 CHR-P, 278 healthy control), co-use of cannabis and tobacco was associated with lower global cognitive performance and lower working memory, verbal learning, and attentional performance compared with healthy control participants. CHR-P individuals who did not use substances also had lower cognitive performance across multiple measures, including global cognition, working memory, verbal learning, visual learning, and attentional performance. The CHR-P non-substance use group also had the lowest social functioning.
CONCLUSIONS: Cannabis and tobacco co-use is associated with lower neurocognitive performance, which may explain the mixed associations between cannabis use and cognitive performance in previous literature.